The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Merck Serono; Pfizer; Roche; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); CanBas (Inst); Cellceutix (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Merck Serono; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology; Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Khanh T Do
No Relationships to Disclose
 
Dejan Juric
Consulting or Advisory Role - Eisai; EMD Serono; Novartis
 
Rinath Jeseslsohn
No Relationships to Disclose
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - Merck; Vertex
 
Ursula A. Matulonis
Consulting or Advisory Role - 2X Oncology; Clovis Oncology; Fujifilm; Geneos; Lilly; Merck; Myriad Genetics
Research Funding - Merck; Novartis
 
Graeme Hodgson
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Emmanuelle DiTomaso
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Kristin Stephens
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
David A. Roth
Employment - Syros Pharmaceuticals
Leadership - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Anthony W. Tolcher
Employment - New Experimental; START
Leadership - Symphony Evolution
Consulting or Advisory Role - AbbVie (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Elekta (Inst); EMD Serono (Inst); Formation Biologics (Inst); Genmab (Inst); Idea Pharma (Inst); Ignyta (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); Alexion Pharmaceuticals (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst)